Provides custom antibody development and related services for research, diagnostic, and therapeutic applications in biotechnology and pharmaceutical industries.
ImmunoPrecise Antibodies Ltd., operating globally with subsidiaries across the United States, Canada, Europe, and Australia, specializes in the production and provision of antibodies and related services. The company serves a diverse research community by offering an extensive portfolio that includes antibodies, enzymes, proteins, and specialized products such as arthritis animal models and organoid growth factors. ImmunoPrecise Antibodies supports research efforts with comprehensive contract research organization services, spanning custom antigen design and manufacturing, B cell sorting and sequencing, phage display technologies, and transgenic animal models for antibody discovery across multiple species.
The company's capabilities extend to advanced antibody engineering, including the production of bi-specific and tri-specific antibodies, as well as VNAR (shark) antibodies. ImmunoPrecise Antibodies excels in DNA cloning, protein purification, and antibody characterization using label-free biosensors. The company also offers services for the development of transient and stable cell lines, antibody optimization, humanization, and cryopreservation, facilitating a wide range of research and therapeutic applications.
Founded in 1983 and headquartered in Victoria, Canada, ImmunoPrecise Antibodies Ltd. actively engages in collaborative research initiatives. It has established strategic partnerships, including agreements with Pierre Fabre S.A. for antibody discovery projects and Elektrofi, Inc. to explore formulations for a high-concentration COVID-19 antibody cocktail, PolyTope TATX-03. Committed to innovation and excellence in antibody technology, ImmunoPrecise Antibodies continues to expand its global footprint in the biopharmaceutical research and development sector.